Trial Profile
Comparative Effectiveness of Long Term Fingolimod Versus Glatiramer Acetate on Brain Atrophy Rates, Cognition and Patient Reported Outcomes in Patients With Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary) ; Glatiramer acetate
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 04 Mar 2022 Status changed from active, no longer recruiting to completed.
- 26 May 2021 Planned primary completion date changed from 1 Mar 2021 to 1 Jun 2021.
- 30 Nov 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.